Aspen Pharma reports rise in profits from new product launches
South Africa’s leading drugmaker Aspen Pharmacare (APN: SJ) has released financial results which show a revenue increase of 27%. The ninth largest generic company in the world said that, for the year ending June 30, 2013, its revenue from continuing operations increased to 19.3 billion rand ($1.94 billion) while operating profit from continuing operations rose by 28% to 5 billion rand.
Earnings per share
Normalized headline earnings, adjusted for specific non-trading items, advanced 32% to 3.8 billion rand. Normalized diluted headline earnings per share from continuing operations increased by 31% to 836 cents. Total distribution of 157 cents per share comprising a cash dividend of 131 cents per ordinary share, and a capital distribution of 26 cents per ordinary share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze